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Research is continuing for synthesizing new molecules with potent pharmacological effects against cancer. In the current 
work we prepared a new tripeptide and investigated its in vitro as well as in vivo antiproliferative effects. Firstly, cyclo  
(Nα-pyrido)-bis-[(L-valinyl)-L-ornithine] was prepared and then tested against 17 different cancer cell lines. Results showed 
that the prepared compound showed increased cytotoxic effects (in terms of decreased IC50 value), which reached about 
20.3, 28.1, 18.3 and 72.3% against RKOP27, K561, GOTO, HT1080 cell lines, respectively, in comparison to standard 
positive controls. Furthermore, cancer cell viability was probably affected through VEGFR-2 kinase inhibition. 
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Introduction 
In nature, protein synthesis including a series of 
peptide coupling reactions (amide bond formation 
between two a-amino acids or peptides) is very 
complex. To solve this problem, the amino acid must 
be transformed to amino acid ester (as intermediates) 
in vivo by a selective activation process catalyzed by 
enzymes. This intermediate is then involved in a 
process mediated by the coordinated interplay of more 
than a hundred macromolecules, including mRNAs, 
tRNAs, activating enzymes and protein factors, in 
addition to ribosomes.1 Amide bond formation 
between an acid and an amine are formally 
condensations, whereas, on mixing an amine with a 
carboxylic acid, an acid– base reaction occurs first to 
form a stable salt. The amide bond formation has to 
fight against adverse thermodynamics as the 
equilibrium shown in the following equation and lies 
on the side of hydrolysis rather than synthesis.2 
 
 
 
Pharmacological studies have proved that many 
peptides, including those synthetic and isolated from 
plants, have a potential antitumor3–5, antiviral6, 
antimicrobial7, and anticancer8 activities. 
Additionally, in our previous work reported that 
heterocyclic candidates possess antimicrobial9–12, 
analgesic and antiinflammatory13, inhibitors of 
VEGFR-2 tyrosine kinase14, and anti -breast cancer15 
activities. In continuation of our interest in the 
chemical and pharmacological properties of  
di-substituted pyridine and amino-acid derivatives,  
we report herein in vitro anti-VEGFR-2 Inhibition  
of cyclo (Nα-pyrido)-bis-[(L-valinyl)-L-ornithine]. 
 
Materials and Methods 
Chemistry 
The tested compound 4 was elucidated previously 
by physical and spectroscopic data by Amr et al.16 
 
Synthesis of cyclo (N
α
-pyrido)-bis-[(L-valinyl)-L-ornthene] (4) 
Compound 4 was synthesized by reaction of 3,  
5-pyridine dicarbony dichloride (1) with L- valine 
methyl ester followed by hydrolysis to 
corresponding diacid 2, which was cyclized with  
L-ornithine methyl ester by using Mixed anhydride 
method according to reported procedure1 to give 
macrocyclic tripeptide 3. Treatment of 3 with 
methanolic sodium hydroxide gave the target 
compound 4. 
—————— 
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Anticancer activity  
The prepared compound was screened for its 
potential antiproliferative effects against different cell 
lines using standard MTT assay.17,18 Cell lines tested 
were chosen to cover a wide range of cancerous 
diseases in different tissues and organs. They included 
cervical carcinoma (KB), ovarian carcinoma (SKOV-3), 
CNS cancer (SF-268), non-small lung cancer (NCI 
H460), colon adenocarcinoma (RKOP27), leukemia 
(HL60, U937 and K562), melanoma (G361 and  
SK-MEL-28), neuroblastoma (GOTO and NB-1), 
cervical carcinoma (HeLa), breast carcinoma  
(MCF-7), fibrosarcoma (HT1080), liver carcinoma 
(HepG2) and prostate carcinoma (PC-3). Cell 
propagation, maintenance and assay procedure were 
followed as per our previous work.17,18 Additionally 
standard reference drugs were used throughout the 
work as positive controls. 
 
In vivo evaluation of antiprostate cancer activity 
The in vivo evaluation was carried out according to 
Kinoyama et al.19 using Male Wistar rat model. The 
protocol followed the ethical guidelines stated for 
animal care. 
 
ELISA determination of kinase inhibition 
The assay was performed according to our 
previously established protocol.17 Briefly, wells 
previously coated with poly (Glu, Tyr) were seeded 
with ATP solution and different serial dilutions of the 
prepared derivative. Results were compared to 
Sorafenib. VEGFR-2 kinase was added to wells to 
start the experiment, and after 1 h at 37 °C, plates 
were washed. The 2nd antibody (Goat anti-mouse IgG 
horseradish peroxidase) was used to complete the 
reaction and the assay followed the standard. 
 
Result and Discussion 
Chemistry 
Cyclo (Nα-pyrido)-bis-[(L-valinyl)-L-ornithine] 4 
was synthesized according to our previous work.16 
Treatment of acid chloride 1 with L-valine methyl 
ester in the presence of trimethylamine gave the 
corresponding bis-ester followed by hydrolyzed with 
sodium hydroxide to corresponding bis-acid 2. 
The latter compound 2 was cyclized with L-ornithine 
methyl ester by using mixed anhydride method  
to give macrocyclic tripeptide ester 3. Hydrolysis of 3 
with methanolic sodium hydroxide afforded the 
corresponding title compound 4 (Scheme 1).  
 
Antiproliverative screening 
After chemical synthesis, the prepared compound 
was then subjected to detailed cytotoxic evaluation 
against different cancer cell lines, both in vivo and in 
vitro. Preliminary results (Fig. 1) revealed that the 
prepared compound was effective against all tested 
cell lines, and showed a varying degree of cell 
toxicity, which was cell type dependent. However, the 
most potential antiproliferative activities obtained 
were noticed against RKOP27, K561, GOTO, 
HT1080, HepG2 and PC3 cell lines. The obtained 
IC50 values for these cell lines recorded 3.45, 4.79, 
3.57, 3.67, 3.45 and 8.81 nM, respectively. 
Furthermore, it can be seen that these obtained IC50 
values were either similar or much less than those 
obtained by the corresponding control drugs; 4.33, 
6.66, 4.37, 13.24, 3.44 and 8.22 nM for Capecitabine, 
Doxorubicin, Imatinib, Gemcitabine and 
Bicalutamide, respectively, for the same order of cell 
lines. From these data, it can be seen that the prepared 
compound showed an increase in its cytotoxic 
activities (in terms of IC50 values), which reached 
about 20.3, 28.1, 18.3 and 72.3% from the values 
obtained for the standard reference drugs. 
Accordingly, the potential of the prepared compound 
can be outlined as a base for preparing 
pharmaceutically drugs active against cancer cells. 
 
In vivo antiprostate cancer activity 
Secondly, the in vivo cytotoxic effects of the 
synthesized derivative against prostate cancer 
developed in mice showed promising results, where 
the obtained ED50 value was significant  
 
 
Scheme 1 — Chemical structure for synthesized compounds16 
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(4.65 ± 0.03 μM) when compared to that obtained for 
the reference drug investigated in vivo (11.60 ± 0.09 μM). 
It can be seen that our prepared compound showed 
about 2.5-folds increase in its effects against in vivo 
prostate cancer model. 
 
Anti-VEGFR-2 inhibition 
In order to gain an overview on the possible mode 
of action, by which the newly synthesized derivative 
may act on cancer cells, the inhibitory effect of the 
synthesized compound was tested against VEGFR-2 
kinase enzyme. The compound exhibited a potential 
effect with an inhibitory IC50 value for VEGFR-2 
kinase of 1.88 nM. Furthermore, comparing our 
derivative with the standard Sorafenib (IC50 2.0 nM) 
showed that compound 4 has increased inhibitory 
effect (about 6% increase). 
Conclusion 
A tripeptide, namely cyclo (Nα-pyrido)-bis- 
[(L-valinyl)-L-ornithine] was prepared by the cyclization 
of the corresponding diacid with L-ornithine methyl 
ester. The prepared tripeptide revealed increased effects 
against RKOP27, K561, GOTO, HT1080 cell lines, 
where the obtained IC50 values for these cell lines 
were lower than their corresponding positive controls. 
Additionally, the compound showed 2.5-folds 
increase in its activity in vivo against PC3 carcinoma. 
Therefore, the new compound can serve as a 
promising molecule in drug discovery. 
 
Abbreviations 
IC50 Half maximal inhibitory concentration  
ED50 Median effective dose 
 
 
Fig. 1 — Antiproliferative activities of the cyclo (Nα-pyrido)-bis-[(L-valinyl)-L-ornithine] towards different cancer cell lines 
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